AMOXICILLIN AND CLAVULANATE POTASSIUM

Post-LOE

amoxicillin and clavulanate potassium

Deva Holdings

ANDAORALTABLET

Approved

Sep 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMOXICILLIN AND CLAVULANATE POTASSIUM (amoxicillin and clavulanate potassium) by Deva Holdings is [see microbiology ()]. Approved for the following infections in adults, skin structure infections urinary tract infections limitations of use, indicating no beta-lactamase production and 10 more indications. First approved in 2023.

Drug data last refreshed 18h ago

Mechanism of Action

[see Microbiology ()].

Indications (13)

the following infections in adults skin structure infections Urinary tract infections Limitations of Use

Worked on AMOXICILLIN AND CLAVULANATE POTASSIUM at Deva Holdings? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.